Ionis Pharmaceuticals, Inc.

Stocks

Real-time Estimate Cboe BZX 15:53:04 2026-09-30 EDT			5-day change	1st Jan Change
44.92 ^USD	-2.12%		+3.60%	-42.47%

09-10	Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-10-2026 08:45 AM
09-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $91 From $93	MT

Published on 09/04/2026 at 11:35 am EDT - Modified on 09/22/2026 at 03:36 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to Ionis conference call to discuss the FDA approval of ZANVASTRO for treatment of Alexander disease. As a reminder, this

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-10	Ionis Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-10-2026 08:45 AM
09-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $91 From $93	MT
09-08	Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial	MT
09-08	Pharvaris' genetic disorder drug meets main goal in late-stage trial	RE
09-07	Soitec in cruise mode, Novartis disappoints
09-07	Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial	DJ
09-04	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- 2nd Update	DJ
09-04	Novartis, Ionis' experimental heart drug misses key goal in closely watched trial	RE
09-04	Stocks to Watch : Ionis Pharmaceuticals, Novartis, Corvex	DJ
09-04	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- Update	DJ
09-04	Ionis-Novartis heart drug misses main goal of late-stage trial	RE
09-04	Ionis Pharmaceuticals Reports Topline Results for Pelacarsen in Lp(A)Horizon Phase 3 Study	CI
09-04	Ionis Pharmaceuticals, Inc. - Special Call
09-04	Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says	MT
09-04	Ionis Pharmaceuticals Gets FDA Approval for Alexander Disease Treatment	MT